TNXP Q3'26 Earnings: revenue estimate is 16.32M USD

What happened

Tonix Pharmaceuticals Holding Corp. is scheduled to report its Q3 2026 results on November 9 before the market opens, with disclosure expected at 9:30 a.m. ET. The revenue estimate is 16.32 million USD, and earnings per share, meaning profit or loss allocated to each share, are anticipated at a loss.

Confirmed

Global impact / market context

The report will show whether revenue came close to the $16.32 million estimate and whether the per-share loss matched expectations. Actual results can change investors’ view of the company’s sales progress and losses, influencing how they position around the stock.

Analyst inference

The article gives a revenue estimate and an expected per-share loss, but no results for the quarter yet. Investors may compare the eventual figures with those estimates: a revenue miss could signal weaker sales than expected, while a smaller loss could indicate better cost control or revenue contribution.

Analyst inference

What to watch

1. Compare reported Q3 revenue with the stated estimate; a higher or lower result would show whether sales exceeded or fell short of expectations for the quarter. Analyst inference
2. Check the reported earnings per share, meaning profit or loss allocated to each share, against the expected loss; a narrower loss may suggest improved financial performance. Analyst inference
3. Look for management’s explanation of revenue and losses in the results announcement; the article supplies estimates and prior-period figures but no causes or Q3 results. Analyst inference

Evidence

• Original source link unavailable